


Gilead to present antiretroviral therapies at virtual APACC 2020 conference

09 October 2020 | News

The abstracts feature clinical and real-world evidence studies evaluating Gilead's antiretroviral therapies in HIV including Biktarvy® and Genvoya® in Asians



Gilead Sciences, Inc. on 9 Oct 2020 announced that four abstracts have been selected for poster presentations at the virtual 2020 Asia Pacific AIDS & Co-infections Conference (APACC) being held from October 15-17, 2020.

The abstracts feature clinical and real-world evidence studies evaluating Gilead's antiretroviral therapies in HIV including Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) and Genvoya® (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide). Two of the abstracts highlight data from Phase 3 studies evaluating virologically suppressed Asian women and virologically suppressed Asian adults who were randomized either to switch to Biktarvy or stay on their baseline regimen.

Other abstracts include the latest post-market surveillance data on the use of Genvoya in routine clinical practice in Korea; as well as a study evaluating the persistence of first-line single tablet regimens and multitablet regimens antiretroviral therapy in HIV-1 patients in Japan.

"The APACC conference is important for continued collaboration and sharing of knowledge with the wider medical and scientific community. We are pleased to be given the opportunity to share our latest clinical data specific to Asians living with HIV at the upcoming forum," said Dr Kuan-Yeh Lee, Director of HIV Medical Affairs, Asia, Gilead Sciences.

Details for all accepted abstracts are as follows:

Paper

Reference #	Type	Paper Title	First Author	Country

P_03	Poster	Efficacy and Safety of Switching to B/F/TAF in Virologically Suppressed Asian Adults Living with HIV	Anchalee Avihingsanon	Thailand
P_05	Poster	Efficacy and Safety of Switching to B/F/TAF in Virologically Suppressed Asian Women living with HIV	Ploenchan Chetchotisakd	Thailand
P_07	Poster	Treatment Persistence among HIV-1 Patients Initiating Antiretroviral Therapy in Japan	Prof Toshio Naito	Japan
P_08	Poster	Safety and Efficacy of Genvoya® (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide, EVG/C/F/TAF) from the 3rd year Post-Market Surveillance (PMS) Data in Korea	Yeon Jae Kim	Korea